Related Experiment Videos
A benefit-cost analysis of mumps vaccine
Abstract:
Applying benefit-cost analysis, we determined the savings in morbidity, mortality, and costs of mumps vaccination in the United States. Using reported mumps incidence rates in a model cohort of 1 million persons followed up for 30 years, mumps vaccination would prevent more than 74,000 cases of mumps and three deaths. Approximating the actual incidence rate of mumps, by assuming that 90% of people are infected by age 30 and 60% of these have had clinical illness, mumps vaccination would prevent more than 540,000 cases of mumps and 23 deaths. A mumps vaccination program, in which mumps was given as part of a measles-mumps-rubella combination, would reduce costs associated with mumps by more than 86%, with a benefit-cost ratio of 7.4:1, using reported incidence rates. The program has a benefit-cost ratio of 39:1 when approximations of actual mumps incidence are used in the analysis. Mumps vaccination is highly cost beneficial.
Insights
Mumps vaccination programs significantly reduce illness, deaths, and costs. A measles-mumps-rubella combination vaccine offers substantial cost benefits, proving highly cost-effective for public health.
Area of Science:
- Public Health
- Epidemiology
- Health Economics
Background:
- Mumps remains a public health concern, causing morbidity and mortality.
- Understanding the economic impact of mumps is crucial for resource allocation.
Purpose of the Study:
- To determine the cost-effectiveness of mumps vaccination in the United States.
- To quantify the savings in morbidity, mortality, and healthcare costs associated with mumps vaccination.
Main Methods:
- Benefit-cost analysis applied to a modeled cohort of 1 million individuals over 30 years.
- Utilized reported and approximated mumps incidence rates to estimate outcomes.
- Assessed vaccination as part of a measles-mumps-rubella (MMR) combination program.
Main Results:
- Mumps vaccination is projected to prevent over 74,000 cases and 3 deaths annually based on reported incidence.
- Using approximated actual incidence, over 540,000 cases and 23 deaths could be averted.
- An MMR vaccination program demonstrated an 86% cost reduction for mumps, with benefit-cost ratios of 7.4:1 and 39:1.
Conclusions:
- Mumps vaccination is a highly cost-beneficial intervention.
- Implementing mumps vaccination, particularly within MMR programs, yields significant economic and health advantages.
- The findings support the widespread adoption of mumps vaccination strategies.